Wall Kristin M, Kilembe William, Haddad Lisa, Vwalika Bellington, Lakhi Shabir, Khu Naw Htee, Brill Ilene, Chomba Elwyn, Mulenga Joseph, Tichacek Amanda, Allen Susan
*Department of Pathology and Laboratory Medicine, Rwanda, Zambia HIV Research Group, School of Medicine, Atlanta, GA; †Hubert, Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA; ‡Department of Epidemiology, Rollins School of Public Health, Laney Graduate School, Emory University, Atlanta, GA; §Department of Gynecology and Obstetrics, Emory University, School of Medicine, Atlanta, GA; ‖Departments of Gynecology and Obstetrics and Internal Medicine, School of Medicine, University of Zambia, Lusaka, Zambia; ¶Department of Epidemiology, Ryals School of Public Health, University of Alabama at Birmingham, Birmingham, AL; and #Ministry of Community Development, Mother and Child Health, Lusaka, Zambia.
J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):345-52. doi: 10.1097/QAI.0000000000000848.
Some studies suggest that hormonal contraception, pregnancy, and/or breastfeeding may influence rates of HIV disease progression.
From 1994 to 2012, HIV discordant couples recruited at couples' voluntary HIV counseling and testing centers in Lusaka were followed 3-monthly. Multivariate survival analyses explored associations between time-varying contraception, pregnancy, and breastfeeding and 2 outcomes among HIV-positive women: (1) time to death and (2) time to antiretroviral treatment (ART) initiation.
Among 1656 female seropositive, male seronegative couples followed for 3359 person-years (PY), 224 women died [6.7/100 PY; 95% confidence interval (CI): 5.8 to 7.6]. After 2003, 290 women initiated ART (14.5/100 PY; 95% CI: 12.9 to 16.2). In a multivariate model of time to death, hormonal implant [adjusted hazard ratio (aHR) = 0.30; 95% CI: 0.10 to 0.98] and injectable (aHR = 0.59; 95% CI: 0.36 to 0.97) were significantly protective relative to nonhormonal method use, whereas oral contraceptive pill (OCP) use was not (aHR = 1.08; 95% CI: 0.74 to 1.57) controlling for baseline HIV disease stage, time-varying pregnancy, time-varying breastfeeding, and year of enrollment. In a multivariate model of time-to-ART initiation, implant was significantly protective (aHR = 0.54; 95% CI: 0.31 to 0.95), whereas OCP (aHR = 0.70; 95% CI: 0.44 to 1.10) and injectable (aHR = 0.85; 95% CI: 0.55 to 1.32) were not relative to nonhormonal method use controlling for variables above, woman's age, and literacy. Pregnancy was not significantly associated with death (aHR = 1.07; 95% CI: 0.68 to 1.66) or ART initiation (aHR = 1.24; 95% CI: 0.83 to 1.86), whereas breastfeeding was protective for death (aHR = 0.34; 95% CI: 0.19 to 0.62) and ART initiation (aHR = 0.49; 95% CI: 0.29 to 0.85).
Hormonal implants and injectables significantly predicted lower mortality; implants were protective for ART initiation. OCPs and pregnancy were not associated with death or ART initiation, whereas breastfeeding was protective for both. Findings from this 18-year cohort study suggest that (1) HIV-positive women desiring pregnancy can be counseled to do so and breastfeed and (2) all effective contraceptive methods, including injectables and implants, should be promoted to prevent unintended pregnancy.
一些研究表明,激素避孕、怀孕和/或母乳喂养可能会影响艾滋病毒疾病的进展速度。
1994年至2012年期间,对在卢萨卡夫妇自愿艾滋病毒咨询和检测中心招募的艾滋病毒不一致夫妇每3个月进行一次随访。多变量生存分析探讨了随时间变化的避孕、怀孕和母乳喂养与艾滋病毒阳性女性的两个结局之间的关联:(1)死亡时间;(2)开始抗逆转录病毒治疗(ART)的时间。
在对1656对女性血清阳性、男性血清阴性的夫妇进行了3359人年(PY)的随访中,224名女性死亡[6.7/100 PY;95%置信区间(CI):5.8至7.6]。2003年后,290名女性开始接受抗逆转录病毒治疗(14.5/100 PY;95% CI:12.9至16.2)。在死亡时间的多变量模型中,与使用非激素方法相比,激素植入物[调整后风险比(aHR)=0.30;95% CI:0.10至0.98]和注射剂(aHR =0.59;95% CI:0.36至0.97)具有显著的保护作用,而口服避孕药(OCP)的使用则没有(aHR =1.08;95% CI:0.74至1.57),该模型控制了基线艾滋病毒疾病阶段、随时间变化的怀孕、随时间变化的母乳喂养和入组年份。在开始抗逆转录病毒治疗时间的多变量模型中,植入物具有显著的保护作用(aHR =0.54;95% CI:0.31至0.95),而与使用非激素方法相比,口服避孕药(aHR =0.70;95% CI:0.44至1.10)和注射剂(aHR =0.85;95% CI:0.55至1.32)则没有,该模型控制了上述变量、女性年龄和识字率。怀孕与死亡(aHR =1.07;95% CI:0.68至1.66)或开始抗逆转录病毒治疗(aHR =1.24;95% CI:0.83至1.86)均无显著关联,而母乳喂养对死亡(aHR =0.34;95% CI:0.19至0.62)和开始抗逆转录病毒治疗(aHR =0.49;95% CI:0.29至0.85)具有保护作用。
激素植入物和注射剂显著预示着较低的死亡率;植入物对开始抗逆转录病毒治疗具有保护作用。口服避孕药和怀孕与死亡或开始抗逆转录病毒治疗均无关联,而母乳喂养对两者均具有保护作用。这项为期18年的队列研究结果表明:(1)可以建议希望怀孕的艾滋病毒阳性女性怀孕并进行母乳喂养;(2)应推广所有有效的避孕方法,包括注射剂和植入物,以防止意外怀孕。